Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 5/2014

01-05-2014 | Diabetes and Cardiovascular Disease (S Malik, Section Editor)

The Role of Genetic Risk Factors in Coronary Artery Disease

Authors: Sonny Dandona, Robert Roberts

Published in: Current Cardiology Reports | Issue 5/2014

Login to get access

Abstract

Genome-wide association studies for coronary artery disease utilizing the case control association study approach has identified 50 genetic risk variants associated with coronary artery disease or myocardial infarction. All of these genetic variants are of genome wide significance and replicated in an independent population. It is of note that 35 of these 50 genetic risk variants act through mechanisms as yet unknown. These findings have great implications for the pathogenesis of atherosclerosis, as well as new targets for the development of novel therapies for the prevention and treatment of CAD. The genetic variant PCSK9 has already led to the development of a monoclonal anti-body which is undergoing assessment in phases I, II, and III clinical trials. This therapy shows very promising results and since it increases removal of LDL-C, it is complementary to current statin therapy. Assessing the beneficial or deleterious effects of a lifelong exposure to a genetic risk variant (Mendelian randomization) will be an important adjunct to clinical trials.
Literature
1.
Brown MS, Goldstein JL. Familial hypercholesterolemia: a genetic defect in the low-density lipoprotein receptor. N Engl J Med. 1976;294(25):1386–90.PubMedCrossRef
2.
Roberts R. New gains in understanding coronary artery disease, interview with Dr. Robert Roberts. Affymetrix Microarray Bull. 2007;3(2):1–4. Spring.
3.
Dandona S et al. Genomics in coronary artery disease: past, present and future. Can J Cardiol. 2010;26(Suppl A):56A–9A.PubMedCrossRef
4.
Pare G. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am J Hum Genet. 2007;80(4):673–82.PubMedCentralPubMedCrossRef
5.
6.
7.
Helgadottir A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491–3.PubMedCrossRef
8.
Helgadottir A et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40(2):217–24.PubMedCrossRef
9.
Hinohara K et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J Hum Genet. 2008;53(4):357–9.PubMedCrossRef
10.
Shen GQ et al. Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arterioscler Thromb Vasc Biol. 2008;28(2):360–5.PubMed
11.
Kumar J et al. Association of polymorphisms in 9p21 region with CAD in North Indian population: replication of SNPs identified through GWAS. Clin Genet. 2011;79(6):588–93.PubMedCrossRef
12.
Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60(18):1715–21.PubMedCrossRef
13.
14.
15.
Jarinova O et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009;29(10):1671–7.PubMed
16.
Burd CE et al. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 2010;6(12):e1001233.PubMedCentralPubMedCrossRef
17.
Harismendy O et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470(7333):264–8. Proposed that interferon-gamma mediates the risk of 9p21 for CAD.PubMedCentralPubMedCrossRef
18.•
Almontashiri NA et al. Interferon-y activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype. J Am Coll Cardiol. 2013;61(2):143–7. These studies indicate the effects of interferon-gamma on expression of P15 and P16 are independent of the 9p21 risk allele.This does not support the hypothesis of 9p21 by Harismendy.PubMed
19.
Dandona S et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol. 2010;56(6):479–86.PubMedCrossRef
20.
Reilly MP et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377(9763):383–92.PubMedCentralPubMedCrossRef
21.
Horne BD et al. Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet. 2008;1(2):85–92.PubMedCentralPubMedCrossRef
22.
Ardissino D et al. Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol. 2011;58(4):426–34.PubMedCrossRef
23.
Chan K et al. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol. 2013;61(9):957–70.PubMedCentralPubMedCrossRef
24.
Preuss M et al. Design of the Coronary ARtery DIsease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) Study: a Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet. 2010;3(5):475–83.PubMedCentralPubMedCrossRef
25.
Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333.8.PubMedCrossRef
26.••
Deloukas P, CARDIoGRAMplusC4D Consortium, et al. Large-scale association analysis identified new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33. This study involving over 240,000 individuals discovers 15 new genetic risk variants for CAD, and confirms 31 previous genetic risk variants for a total of 46. This study indicates all of the genetic variants are associated with CAD, having a P value of genome wide significance and the association has been replicated in an independent population.PubMedCrossRef
27.
Lu X et al. Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet. 2012;44(8):890–4.PubMedCentralPubMedCrossRef
28.
IBC 50 K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 2011;7(9):e1002260.CrossRef
29.
He M et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012;32(9):2314–20.PubMedCentralPubMed
30.
Gill JC et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–5.PubMed
31.
Ripatti S et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376(9750):1393–400.PubMedCentralPubMedCrossRef
32.
Thanassoulis G et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5(1):113–21.PubMedCentralPubMedCrossRef
33.
Roberts R. PCSK9 inhibition - a new thrust in the prevention of heart disease: genetics does it again. Can J Cardiol. 2013;29(8):899–901.PubMedCrossRef
34.
Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.PubMedCrossRef
35.
Wierzbicki AS et al. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs. 2012;21(5):667–76.PubMedCrossRef
36.
Stein EA et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–18.PubMedCrossRef
37.
Ni YG et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52(1):78–86.PubMedCentralPubMedCrossRef
Metadata
Title
The Role of Genetic Risk Factors in Coronary Artery Disease
Authors
Sonny Dandona
Robert Roberts
Publication date
01-05-2014
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 5/2014
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-014-0479-2

Other articles of this Issue 5/2014

Current Cardiology Reports 5/2014 Go to the issue

Global Cardiovascular Health (SC Smith, Section Editor)

The Global Burden of Cardiovascular Diseases: A Challenge to Improve

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Diabetes and Associated Complications in the South Asian Population

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

New Insights from Major Prospective Cohort Studies with Cardiac Nuclear Imaging

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

4D Flow Imaging: Current Status to Future Clinical Applications

Global Cardiovascular Health (SC Smith, Section Editor)

“East Asian Paradox”: Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome

Interventional Cardiology (S Rao, Section Editor)

Current Status of Percutaneous PFO Closure